Post Exposure Prophylaxis News and Research

RSS

New HIV prevention guidelines from Canada released

New guidelines for Canada have been published in the Canadian Medical Association Journal online this week that outline the use of new anti-HIV medications among high risk populations who are at risk of contracting HIV from getting the dreaded infection. These new guidelines aim to provide the clinicians with resources and support he added.

27 Nov 2017

HIV prevention drug to be trialed by Britain's NHS

After a High Court case, an HIV prevention drug is soon to be available on the NHS. NHS England has issued a statement saying that pre-exposure prophylaxis (PrEP) treatment for HIV shall be available to an initial 10,000 people for a trial period of three years.

3 Aug 2017

Measles outbreak - 35 reported deaths in Europe

Over the last 12 month, there have been 35 reported deaths due to the ongoing measles outbreak in the WHO European Region says a new report.

12 Jul 2017

Treatment with interferon may ease symptoms of Ebola patients

A pilot study of a class of drugs used to treat hepatitis and some forms of multiple sclerosis has been shown for the first time to ease symptoms of Ebola patients, while also increasing their survival.

21 Mar 2017

O'Neill Institute, NMAC release first of two reports to help prevent HIV in communities of color

Two HIV policy experts from the O'Neill Institute for National and Global Health Law at Georgetown Law working in partnership with NMAC have released the first of two reports to help prevent HIV in communities of color.

15 Dec 2016

Rabies vaccine stored at warmer temperatures can protect against disease, WSU research shows

A Washington State University-led research team determined rabies vaccines stored at warmer temperatures still protect against the disease in dogs.

24 Oct 2016

New antibody-based therapy may provide better strategy for long-term control of HIV

The development of antiretroviral therapy, a combination of drugs that slows the replication of HIV in the body, has transformed the treatment of this infection. What was once a certain death sentence is now a chronic condition that people can live with for decades.

9 May 2016

Researchers use quick screening method to identify, test promising anti-Ebola drugs

A quick screening method has been used for the first time in a standard open laboratory to identify and test promising anti-Ebola drugs. This approach increases the possibility of finding new therapies faster.

12 Jan 2016

New framework launched for global elimination of human rabies

A new framework to eliminate human rabies and save tens of thousands of lives each year has been launched today by the World Health Organization, the World Organization for Animal Health, the Food and Agriculture Organization of the United Nations and the Global Alliance for the Control of Rabies.

10 Dec 2015

Antiviral-based therapies have potential to protect humans from deadly Ebola virus

For the first time, UK physicians have demonstrated that antiviral-based therapies have the potential to protect humans from the deadly Ebola virus. The report, published in The Lancet Infectious Diseases journal, describes a case-series of eight British health-care workers who were evacuated to the Royal Free Hospital in London, UK after possible accidental exposure to Ebola virus in Sierra Leone between January and March 2015.

26 Aug 2015

Bioethics Commission makes recommendations on preparedness for public health emergencies

Today the Presidential Commission for the Study of Bioethical Issues (Bioethics Commission) reported that the federal government has both a prudential and a moral responsibility to actively participate in coordinated global responses to public health emergencies wherever they arise.

28 Feb 2015

Elusys presents positive results of obiltoxaximab for treating inhalational anthrax, post-exposure prophylaxis

Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, presented data demonstrating that obiltoxaximab (ETI-204) demonstrated a statistically significant survival benefit across a range of disease severity in animal model studies assessing treatment of inhalational anthrax, as well as effectiveness in post-exposure prophylaxis.

13 Feb 2015

New guidelines integrate biomedical advances and behavioral interventions for HIV people

In an innovative approach to HIV prevention, an interdisciplinary group of experts has come together for the first time to lay out a framework of best practices to optimize the role of the clinician in achieving an AIDS-free generation.

21 Jul 2014

Emergent BioSolutions reports total revenue of $53.9 million for Q1 2014

Emergent BioSolutions Inc. reported total revenue for Q1 2014 of $53.9 million as compared to $43.1 million in 2013. In addition, Q1 2014 net loss was $20.2 million, or $0.55 per share, as compared to a net loss of $8.1 million, or $0.22 per share, in 2013.

9 May 2014

FDA grants Orphan Drug Designation to Emergent BioSolutions' BioThrax for PEP of anthrax disease

Emergent BioSolutions Inc. announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to BioThrax (Anthrax Vaccine Adsorbed) for post-exposure prophylaxis (PEP) of anthrax disease resulting from suspected or confirmed exposure to Bacillus anthracis.

21 Apr 2014

Bioethics Commission releases ethical recommendations to manage incidental and secondary findings

Researchers conduct a memory study, scan a participant's brain, and find more than they bargain for: a tumor. What do the researchers owe the participant? What does the participant want to know?

13 Dec 2013

Emergent BioSolutions enters into definitive agreement to acquire Cangene

Emergent BioSolutions Inc.announced that it has entered into a definitive agreement with Cangene Corporation (TSX: CNJ) under which Emergent will acquire all of the outstanding common shares of Cangene in an all-cash transaction valued at $3.24 per share on a fully diluted basis for an aggregate purchase price of $222 million.

12 Dec 2013

Emergent BioSolutions acquires Bracco Diagnostics' Healthcare Protective Products Division

Emergent BioSolutions Inc. announced today that it has closed on its acquisition of Bracco Diagnostics Inc.'s Healthcare Protective Products Division. This acquisition, which includes the RSDL (decontamination lotion) product that is cleared for marketing by the U.S. Food and Drug Administration for removal or neutralization of chemical warfare agents from the skin, diversifies and broadens Emergent's biodefense franchise into the chemical countermeasure market.

2 Aug 2013

Viewpoints: A 'clever' fix for contraception coverage; Sanjay Gupta warns doctors to pay attention to health overhaul

Many nonprofit religious organizations have balked at having to insure their employees' birth control -- because they don't believe in artificial contraception -- under the Affordable Care Act. On Friday, the Obama administration announced a solution to this problem. The new health care law guarantees access to preventive services, and contraception falls, appropriately, into that category (Carla Hill, 6/28).

2 Jul 2013

Theoretical mathematical models offer insights into therapeutic, prevention strategies for HIV

The first few hours to days following exposure to human immunodeficiency virus can be of critical importance in determining if infection occurs in a patient. But the low numbers of viruses and infected cells at this stage makes it very difficult to study these events in humans or animal models.

1 Jun 2013